ZVRA
ZEVRA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.17
+8.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 147.8M | 106.5M | 23.6M | 27.5M | 10.2M |
| Cost of Revenue | 7.1M | 16.5M | 7.4M | 2.9M | 222.0K |
| Gross Profit | 140.7M | 90.0M | 16.2M | 24.5M | 9.9M |
| Operating Expenses | |||||
| R&D Expense | 16.4M | 12.7M | 42.1M | 39.8M | 19.8M |
| SG&A Expense | 76.8M | 77.6M | 54.9M | 35.1M | 15.0M |
| General & Admin Expense | — | — | — | — | 15.3M |
| Selling & Marketing Expense | 16.6M | — | — | — | (305.0K) |
| Other Expenses | 632.0K | 3.9M | 6.2M | (775.0K) | 17.7M |
| Total Operating Expenses | 93.9M | 94.2M | 103.2M | 74.1M | 52.5M |
| Cost and Expenses | 100.9M | 110.7M | 110.6M | 77.1M | 52.7M |
| Operating Income (EBIT) | 46.5M | (4.2M) | (87.0M) | (49.6M) | (42.6M) |
| Non-Operating | |||||
| Interest Income | 5.3M | 6.9M | 2.2M | 4.5M | 1.5M |
| Interest Expense | 3.7M | 8.0M | 7.4M | 1.5M | 335.0K |
| Net Interest Income | 1.6M | (1.0M) | (5.2M) | 3.0M | 1.2M |
| Other Non-Op Income/Expense | 43.5M | 90.9M | (3.1M) | 3.6M | 15.8M |
| Non-Operating Income (excl Interest) | (35.6M) | (98.9M) | (4.2M) | (5.1M) | (16.1M) |
| EBT (Pre-Tax Income) | 90.0M | 86.7M | (90.1M) | (46.0M) | (26.8M) |
| Income Tax Expense | 10.9M | 3.4M | 15.4M | — | (33.0K) |
| Bottom Line | |||||
| Net Income | 78.0M | 83.2M | (105.5M) | (46.0M) | (26.8M) |
| Earnings from Cont. Ops | 78.0M | 83.2M | (105.5M) | (46.0M) | (26.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 78.0M | 77.6M | (105.5M) | (46.0M) | (26.8M) |
| Per Share | |||||
| Basic EPS | $1.28 | $1.40 | ($2.28) | ($1.30) | ($0.78) |
| Diluted EPS | $1.20 | $1.35 | ($2.28) | ($1.30) | ($0.78) |
| Revenue Per Share | $2.49 | $1.92 | $0.51 | $0.77 | $0.29 |
| Shares | |||||
| Basic Shares Outstanding | 59.4M | 55.3M | 46.3M | 35.5M | 34.5M |
| Diluted Shares Outstanding | 61.7M | 57.3M | 46.3M | 35.5M | 34.5M |
| Profitability Metrics | |||||
| EBITDA | 83.2M | 98.7M | (76.4M) | (43.5M) | (25.5M) |
| D&A | 1.1M | 4.1M | 6.4M | 1.0M | 944.0K |
| EBIT | 70.5M | 94.7M | (82.8M) | (44.5M) | (26.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026